Original data asset
GLP-1 Access and Safety Tracker
Dated source checks help separate approved products, shortage records, safety warnings, compounded-drug enforcement, and retatrutide investigational status.
Direct answer
Source-dated status matters for topics that change often: FDA-approved product status, FDA shortage records, compounded-product warnings, enforcement updates, and retatrutide investigational status.
Medication choice, medication purchasing, provider choice, and compounded-product suitability require licensed clinical or pharmacy guidance. FDA product labeling and the FDA Drug Shortages Database remain controlling sources for product and shortage information.
Source categories
Relevant sources include FDA-approved GLP-1 and related incretin products, FDA Drug Shortages Database status, FDA safety, compounding, and enforcement updates, patient-safety topics for clinician or pharmacist discussion, and retatrutide research status with clear language that it is investigational.
Provider comparisons, product rankings, individual insurance estimates, cash-pay quotes, health-information collection, and pharmacy links are not included.
How to read source dates
Source dates matter because FDA shortage status can change and local pharmacy availability can differ from national shortage status.
If you are currently using, considering, or having trouble obtaining a GLP-1 medication, discuss the situation with a licensed clinician or pharmacist. Do not start, stop, switch, split, skip, restart, or change a medication dose based on a tracker row.
How shortage status is read
The FDA Drug Shortages Database is the controlling source for current national shortage status. Manufacturer availability statements, local pharmacy inventory, social media reports, clinic marketing, and patient anecdotes are not replacements for the FDA database.
Each row records the product or active ingredient checked, the source category, the date checked, the source URL, and whether FDA, manufacturer, or enforcement status changed. Rows without a current FDA database check say status verification pending rather than making a current-status claim.
How compounding status is read
Compounded drugs are not FDA-approved. FDA says consumers and health professionals rely on the FDA drug approval process for verification of safety, effectiveness, and quality, and that unnecessary compounded-drug use may expose patients to serious health risks.
FDA-approved products and compounded products are not the same category. Compounded GLP-1 products are not generic versions of brand medications, and compounded-product claims need current FDA sources.
How safety updates are read
Safety rows are dated and source-backed. They are not treatment instructions. Topics include FDA warnings about unapproved GLP-1 drugs used for weight loss, compounded injectable semaglutide dosing errors, fraudulent products, improper shipping or storage, illegal online sales, warning letters, enforcement announcements, and label updates that affect patient safety education.
FDA reporting resources can be useful, but adverse-event management belongs with a licensed clinician, pharmacist, urgent care, emergency services, or poison control as appropriate for the situation.
Retatrutide status boundary
Misleading retatrutide access claims are a safety risk because retatrutide is not FDA-approved.
Retatrutide is investigational and is not FDA-approved. Source-dated research status is different from clinical use, purchasing, compounding, prescribing, dosing, or provider access.
Before a clinical conversation
Before a clinician or pharmacist conversation, identify the exact product, active ingredient, approval status, warning topics, and source questions that matter.
Medication choice, dosing, pharmacy selection, and treatment planning require a licensed clinician who can evaluate medical history, contraindications, monitoring needs, other medications, pregnancy plans, and current product labeling.
Care decisions belong with clinicians
Changing medication, managing symptoms, preparing injections, and interpreting a personal risk profile require clinician or pharmacist guidance.
Product labels, pharmacist counseling, and clinician follow-up remain the controlling sources for patient-specific decisions.
Source limits
Approval status, compounding policy, shortage status, product labels, and trial status can change. The current source date matters when reading high-change medical or regulatory claims.
Trial evidence applies to the studied population and endpoint. It is not a promise of an individual result.
Source update frequency
FDA shortage status can change weekly during active supply changes and should be treated as at least monthly or event-triggered afterward. FDA unapproved GLP-1 and compounding information can change with enforcement or policy updates. FDA product labels can change when safety, indication, or labeling updates occur.
Retatrutide ClinicalTrials.gov records and Lilly sponsor-reported releases can change the research-status picture. Sponsor updates are not regulatory status.
Source-dated tracker rows checked on 2026-05-26
| Category | Checked status | Source and update rule |
|---|---|---|
| Semaglutide | FDA-approved semaglutide products are label-specific. Compounded semaglutide products are not FDA-approved. | Checked against DailyMed WEGOVY, OZEMPIC, and RYBELSUS labels plus FDA unapproved GLP-1 and dosing-error pages. Labels update quarterly or when FDA changes. FDA compounding and shortage pages update monthly or when FDA changes. |
| Tirzepatide | FDA-approved tirzepatide products are label-specific. Compounded tirzepatide products are not FDA-approved. | Checked against DailyMed MOUNJARO and ZEPBOUND labels plus FDA unapproved GLP-1 and compounding-policy pages. Labels update quarterly or when FDA changes. FDA compounding and shortage pages update monthly or when FDA changes. |
| Compounded GLP-1 products | Compounded GLP-1 products are not FDA-approved, and FDA has warned about unapproved GLP-1 drugs, dosing errors, and counterfeit or fraudulent products. | Checked against FDA unapproved GLP-1 concerns, compounding Q&A, compounder policy, and compounded semaglutide dosing-error alert. Updated monthly or when FDA changes. |
| FDA shortage and access context | National shortage, supply, and enforcement policy are source-dated and can differ from local pharmacy availability. | FDA Drug Shortages Database and FDA compounding-policy pages are the controlling sources. Updated whenever FDA changes shortage or enforcement status. |
| Retatrutide / LY3437943 | Investigational only. Not FDA-approved. Not prescription access or compounding access content. | Checked against FDA unapproved GLP-1 concerns, ClinicalTrials.gov records, and clearly labeled Lilly sponsor releases. FDA, ClinicalTrials.gov, and sponsor-reported sources update monthly or when status changes. |
Questions
Does the tracker show local pharmacy availability?
No. Local inventory can differ from national shortage or regulatory status and should be discussed with a pharmacist or prescriber.
Why is retatrutide included if it is not approved?
Misleading retatrutide access or compounding claims are a safety risk. Retatrutide remains investigational, not FDA-approved, and not prescription-access content.
Sources
- FDA concerns with unapproved GLP-1 drugs used for weight loss, U.S. Food and Drug Administration. Accessed 2026-05-26.
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, U.S. Food and Drug Administration. Accessed 2026-05-26.
- FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list, U.S. Food and Drug Administration. Accessed 2026-05-26.
- FDA drug shortages, U.S. Food and Drug Administration. Accessed 2026-05-26.
- FDA alert on dosing errors associated with compounded injectable semaglutide products, U.S. Food and Drug Administration. Accessed 2026-05-26.
- Compounding and the FDA: questions and answers, U.S. Food and Drug Administration. Accessed 2026-05-26.
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight, ClinicalTrials.gov. Accessed 2026-05-26.
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity, ClinicalTrials.gov. Accessed 2026-05-26.
- Lilly retatrutide Phase 3 obesity trial topline results, Eli Lilly and Company via PR Newswire. Accessed 2026-05-26.